Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

DNA vaccination with an insulin construct and a chimeric protein binding to both CTLA4 and CD40 ameliorates type 1 diabetes in NOD mice

Gene Therapy volume 12, pages 1679–1685 (2005)Cite this article

Abstract

Type 1 diabetes (T1D), a T-cell-mediated autoimmune disease, could be attributed to many defects in nonobese diabetic (NOD) mice, including deficient expressions of costimulatory molecules that impair antigen presentation. Thus, this deficient antigen presentation may result in a reduced ability to induce a tolerogenic response through negative selection/regulation of autoreactive T cells. Improperly activated T cells seem to be able to induce autoimmune responses causing diabetes. To re-establish tolerance to autoantigens by modulating costimulation, we constructed and tested a new type of DNA vaccine encoding a membrane-bound preproinsulin (mbPPI) and a chimeric gene vector encoding mutant B7.1/CD40L (mB7.1/CD40L) fusion protein. This mutant B7.1 binds CTLA4 but not CD28. We report that young NOD mice immunized with mbPPI along with mB7.1/CD40L DNA vectors significantly reduced diabetes incidence while treatment with CTLA4/IgG1 exacerbated diabetes. In conclusion, the combination of mbPPI and mB7.1/CD40L was able to protect against autoimmunity and diabetes in NOD mice possibly by promoting a more efficient presentation of autoantigen PPI and inducing specific tolerance to PPI by negatively regulating autoreactive T cells.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

References

  1. Adorini L, Gregori S, Harrison LC . Understanding autoimmune diabetes: insights from mouse models. Trends Mol Med 2002; 8: 31–38.

    Article  CAS  PubMed  Google Scholar 

  2. Serreze DV, Leiter EH . Genes and cellular requirements for autoimmune diabetes susceptibility in nonobese diabetic mice. Curr Dir Autoimmun 2001; 4: 31–67.

    Article  CAS  PubMed  Google Scholar 

  3. Suarez-Pinzon WL, Rabinovitch A . Approaches to type 1 diabetes prevention by intervention in cytokine immunoregulatory circuits. Int J Exp Diabetes Res 2001; 2: 3–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Gottlieb PA, Hayward AR . Cytokine and immunosuppressive therapies of type 1 diabetes mellitus. Endocrinol Metab Clin North Am 2002; 31: 477–495.

    Article  CAS  PubMed  Google Scholar 

  5. Rudy G et al. Similar peptides from two beta cell autoantigens, proinsulin and glutamic acid decarboxylase, stimulate T cells of individuals at risk for insulin-dependent diabetes. Mol Med 1995; 1: 625–633.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. French MB et al. Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice (published erratum appears in Diabetes 1997 May 46:924). Diabetes 1997; 46: 34–39.

    Article  CAS  PubMed  Google Scholar 

  7. Chen W et al. Evidence that a peptide spanning the B–C junction of Proinsulin is an early autoantigen epitope in the pathogenesis of type 1 diabetes. J Immunol 2001; 167: 4926–4935.

    Article  CAS  PubMed  Google Scholar 

  8. Ivana D-B, Bernhard OB, Ziegler A-G . Predominantly recognized proinsulin T helper cell epitopes in individuals with and without islet cell autoimmunity. J Autoimmun 2002; 18: 55–66.

    Article  Google Scholar 

  9. Dubois-Lafforgue D et al. Proinsulin 2 knockout NOD mice: a model for genetic variation of insulin gene expression in type 1 diabetes. Diabetes 2002; 51 (Suppl 3): S489–S499.

    Article  CAS  PubMed  Google Scholar 

  10. Thebault-Baumont K et al. Acceleration of type 1 diabetes mellitus in proinsulin 2-deficient NOD mice. J Clin Invest 2003; 111: 851–857.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Dahlen E, Hedlund G, Dawe K . Low CD86 expression in the nonobese diabetic mouse results in the impairment of both T cell activation and CTLA-4 up-regulation. J Immunol 2000; 164: 2444–2456.

    Article  CAS  PubMed  Google Scholar 

  12. Strid J et al. A defect in bone marrow derived dendritic cell maturation in the nonobesediabetic mouse. Clin Exp Immunol 2001; 123: 375–381.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Piganelli JD, Martin T, Haskins K . Splenic macrophages from the NOD mouse are defective in the ability to present antigen. Diabetes 1998; 47: 1212–1218.

    Article  CAS  PubMed  Google Scholar 

  14. Rapoport MJ et al. Thymic T cell anergy in autoimmune nonobese diabetic mice is mediated by deficient T cell receptor regulation of thr pathway of p21 ras activation. J Exp Med 1993; 177: 1221–1226.

    Article  CAS  PubMed  Google Scholar 

  15. Serreze DV . Autoimmune diabetes results from genetic defects manifest by antigen presenting cells. FASEB J 1993; 7: 1092–1096.

    Article  CAS  PubMed  Google Scholar 

  16. Salojin K et al. Impaired plasma membrane targeting of Grb2-murine son of sevenless (mSOS) complex and differential activation of the Fyn-T cell receptor (TCR)-ζ-Cb1 pathway mediate T cell hyporesponsiveness in autoimmune nonobese diabetic mice. J Exp Med 1997; 186: 887–897.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Serreze DV, Gaskins HR, Leiter EH . Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice. J Immunol 1993; 150: 2534–2543.

    CAS  PubMed  Google Scholar 

  18. Piganelli JD et al. Cytotoxic T lymphocyte antigen 4 (CD152) regulates self-reactive T cells in BALB/c but not in the autoimmune NOD mouse. J Autoimmun 2000; 14: 123–131.

    Article  CAS  PubMed  Google Scholar 

  19. Lenschow DJ et al. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 1996; 5: 285–293.

    Article  CAS  PubMed  Google Scholar 

  20. Arreaza GA et al. Neonatal activation of CD28 signaling overcomes T cell anergy and prevents autoimmune diabetes by an IL-4-dependent mechanism. J Clin Invest 1997; 100: 2243–2253.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Lenschow DJ et al. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J Exp Med 1995; 181: 1145–1155.

    Article  CAS  PubMed  Google Scholar 

  22. Ueda H et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423: 506–511.

    Article  CAS  PubMed  Google Scholar 

  23. Prud'homme GJ . Gene therapy of autoimmune diseases with vectors encoding regulatory cytokines or inflammatory cytokine inhibitors. J Gene Med 2000; 2: 222–232.

    Article  CAS  PubMed  Google Scholar 

  24. Garren H, Steinman L . DNA vaccination in the treatment of autoimmune diseases. Curr Dir Autoimmun 2000; 2: 203–216.

    Article  CAS  PubMed  Google Scholar 

  25. Scheerlinck JY . Genetic adjuvants for DNA vaccines. Vaccine 2001; 19: 2647–2656.

    Article  CAS  PubMed  Google Scholar 

  26. Prud'homme GJ, Chang Y, Li X . Immunoinhibitory DNA vaccine protects against autoimmune diabetes through cDNA encoding a selective CTLA-4 (CD152) ligand. Human Gene Ther 2002; 13: 395–406.

    Article  CAS  Google Scholar 

  27. Polanski M, Melican NS, Zhang J, Weiner HL . Oral administration of the immunodominant B-chain of insulin reduces diabetes in a co-transfer modes of diabetes in the NOD mouse and is associated with a switch from Th1 to Th2 cytokines. J Autoimmun 1997; 10: 339–346.

    Article  CAS  PubMed  Google Scholar 

  28. Harrison LC, Dempsey-Collier M, Kramer DR, Takihashi K . Aerosol insulin induces regulatory CD8 gamma/delta T cells that prevent murine insulin-dependent diabetes. J Exp Med 1996; 184: 2167–2174.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Ramiya VK, Shang XZ, Wasserfall CH, Maclaren NK . Effect of oral and intravenous insulin and glutamic acid decarboxylase in NOD mice. Autoimmunity 1997; 26: 139–151.

    Article  CAS  PubMed  Google Scholar 

  30. Hutchings P, Cooke A . Comparative study of the protective effect afforded by intravenous administration of bovine or ovine insulin to young NOD mice. Diabetes 1995; 44: 906–910.

    Article  CAS  PubMed  Google Scholar 

  31. Daniel D, Wegmann DR . Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin B-(9-23). Proc Natl Acad Sci USA 1996; 93: 956–960.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Chen W et al. Evidence that a peptide spanning the B–C junction of proinsulin I is an early autoantigen epitope in the pathogenesis of type 1 diabetes. J Immunol 2001; 167: 4926–4935.

    Article  CAS  PubMed  Google Scholar 

  33. Martinez NR et al. Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J Clin Invest 2003; 111: 1365–1371.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Halbout P et al. T cell response to preproinsulin I and II in the nonobese diabetic mouse. J Immunol 2002; 169: 2436–2443.

    Article  CAS  PubMed  Google Scholar 

  35. Urbanek-Ruiz I et al. Immunization with DNA encoding an immunodominant peptide of insulin prevents diabetes in NOD mice. Clin Immunol 2001; 100: 164–171.

    Article  CAS  PubMed  Google Scholar 

  36. Bot A et al. Plasmid vaccination with insulin B chain prevents autoimmune diabetes in nonobese diabetic mice. J Immunol 2001; 167: 2950–2955.

    Article  CAS  PubMed  Google Scholar 

  37. Weaver Jr DJ, Liu B, Tisch R . Plasmid DNAs encoding insulin and glutamic acid decarboxylase 65 have distinct effects on the progression of autoimmune diabetes in nonobese diabetic mice. J Immunol 2001; 167: 586–592.

    Article  CAS  PubMed  Google Scholar 

  38. Karges W et al. Induction of autoimmune diabetes through insulin (but not GAD65) DNA vaccination in nonobese diabetic and in RIP-B7.1 mice. Diabetes 2002; 51: 3237–3244.

    Article  CAS  PubMed  Google Scholar 

  39. van Essen D, Kikutani H, Gray D . CD40 ligand-transduced co-stimulation of T cells in the development of helper function. Nature 1995; 378: 620–623.

    Article  CAS  PubMed  Google Scholar 

  40. Goodnow CC . Pathways for self-tolerance and treatment of autoimmune diseases. The Lancet 2001; 357: 2115–2121.

    Article  CAS  Google Scholar 

  41. Lederman S . The role of CD154 (CD40-ligand) in costimulation. Transplantation Proceedings 2001; 33: 202–206.

    Article  CAS  PubMed  Google Scholar 

  42. Williams JA, Sharrow SO, Adams AJ, Hodes RJ . CD40 ligand functions non-cell autonomously to promote deletion of self-reactive thymocytes. J Immunol 2002; 168: 2759–2765.

    Article  CAS  PubMed  Google Scholar 

  43. Li R, Page DM . Requirement for a complex array of costimulators in the negative selection of autoreactive thymocytes in vivo. J Immunol 2001; 166: 6050–6056.

    Article  CAS  PubMed  Google Scholar 

  44. Tian J et al. Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice. J Immunol 2001; 167: 1081–1089.

    Article  CAS  PubMed  Google Scholar 

  45. Steptoe RJ, Ritchie JM, Harrison LC . Transfer of hematopoietic stem cells encoding autoantigen prevents autoimmune diabetes. J Clin Invest 2003; 111: 1357–1363.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Prud'homme GJ, Chang Y . Prevention of autoimmune diabetes by intramuscular gene therapy with a nonviral vector encoding an interferon-γ receptor/IgG1 fusion protein. Gene Therapy 1999; 6: 771–777.

    Article  CAS  PubMed  Google Scholar 

  47. Chang Y, Prud'homme GJ . Intramuscular administration of expression plasmids encoding interferon-gamma-receptor/IgG1 or IL-4/IgG1 chimeric proteins protects from autoimmunity. J Gene Med 1999; 1: 415–423.

    Article  CAS  PubMed  Google Scholar 

  48. Guo Y, Wu Y, Kong X, Liu Y . Identification of conserved amino acids in murine B7-1IgV domain critical for CTLA4/CD28:B7 interaction by site-directed mutagenesis: a novel structural model of the binding site. Mol Immunol 1998; 35: 215–225.

    Article  CAS  PubMed  Google Scholar 

  49. Guo Y et al. Mutational analysis of an alternatively spliced product of B7 defines its CD28/CTLA4-binding site on immunoglobulin C domain. J Exp Med 1995; 181: 1345–1355.

    Article  CAS  PubMed  Google Scholar 

  50. Lawson BR et al. Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc. J Clin Invest 2000; 106: 207–215.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported by Research Advisory Committee of Children's Hospital of Pittsburgh and Juvenile Diabetes Research Foundation International.

Author information

Authors and Affiliations

  1. Division of Immunogenetics, Department of Pediatrics, University of Pittsburgh, School of Medicine, Rangos Research Center, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA

    Y Chang, S Yap, X Ge, J Piganelli, S Bertera, C Mathews & M Trucco

  2. Diabetes Institute of University of Pittsburgh, Children's Hospital of Pittsburgh, Pittsburgh, PA, USA

    Y Chang, J Piganelli, N Giannokakis, C Mathews & M Trucco

  3. Department of Laboratory Medicine and Pathobiology, St Michael's Hospital and University of Toronto, Toronto, Ontario, Canada

    G Prud'homme

Authors
  1. Y Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Yap
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. X Ge
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Piganelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Bertera
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N Giannokakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Mathews
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Prud'homme
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Trucco
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Chang, Y., Yap, S., Ge, X. et al. DNA vaccination with an insulin construct and a chimeric protein binding to both CTLA4 and CD40 ameliorates type 1 diabetes in NOD mice. Gene Ther 12, 1679–1685 (2005). https://doi.org/10.1038/sj.gt.3302578

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302578

Keywords

  • type 1 diabetes (T1D)
  • mB7.1/CD40L
  • autoimmunity
  • nonobese diabetic (NOD) mouse, tolerance

This article is cited by

Search

Advanced search

Quick links